(Stamford, CT)—CircleLink Health LLC announces that The University of Maryland, Vanderbilt University and The University of Pittsburgh Medical Centers are conducting a study employing its CarePlanManagerTM patient engagement platform to determine the impact of accelerated mobile phone based reporting of symptoms in patients with Inflammatory Bowel Disease (IBD). This study, called “Tele-IBD” represents a novel application of easily accessible mobile technology to improve IBD patient outcomes, self-management and quality of life, at the same time reducing care costs, and treatment speed.
By automatically engaging patients on their mobile phones, CarePlanManager regularly (weekly or bi-weekly) assesses the extent of their Crohn’s and Colitis symptoms based on a range of questions. Then, based on a defined algorithm, it automatically assigns patients into green, yellow or red zones. As part of the automated response, a personalized action plan is delivered to each patient based on which severity zone they are in; yellow or red zones also cause health care professionals (HCP’s) to be immediately alerted allowing for early interventions. The system also tracks and assesses medication use, side effects and weight. Importantly, patients can also use their mobile phones to contact the CarePlanManager system to report “flare-ups” as they occur. The system then automatically takes them through an assessment and delivers an action plan.
“We are enthusiastic about the many advantages CarePlanManager offers telemedicine systems like Tele-IBD,” said Dr. Raymond K. Cross, Jr., Directory of the Inflammatory Bowel Disease Program, and Gastroenterologist and Associate Professor of Medicine, Division of Gastroenterology and Hepatology, at the University of Maryland School of Medicine. “CarePlanManager helps improve outcomes and costs by providing:
- More frequent monitoring and earlier medical intervention
- Better adherence to medications
- Patient self-management
- Improved knowledge through frequent education messages.”
Dr. Cross Continues: “During the study, patients have been very enthusiastic about using CarePlanManager. Adherence to self-testing has been excellent and loss to follow up has been very low. Anticipating that outcomes improve as we expect, CarePlanManager is exactly what forward-thinking medical systems and/or payers should be using.”
The Crohn’s and Colitis project results to date reinforce the value of using CarePlanManager to successfully drive patient engagement and outcomes in chronic illnesses, and its effective use with patients across various socio-economic and skill levels.